2 completed, 1 available, 1 enrolling by invitation. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Enrolling by invitation 1 |
Follow Alterity Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France ATH434 - Multiple System Atrophy | Phase 2 | Enrolling by invitation | Alterity Therapeutics | 7 | 2026-10-01 | 2026-10-09 |
| A Biomarker Study of ATH434 in Participants With MSA ATH434 - Multiple System Atrophy | Phase 2 | Completed | Alterity Therapeutics | 10 | 2023-05-23 | 2025-04-01 |
| Study of ATH434 in Participants with Multiple System Atrophy ATH434 dose level 1, ATH434 dose level 2, Placebo - Multiple System Atrophy | Phase 2 | Completed | Alterity Therapeutics | 77 | 2022-07-01 | 2024-12-13 |
| Post-Trial Access to ATH434 for Patients With Multiple System Atrophy ATH434 - Multiple System Atrophy | Available | Alterity Therapeutics | 2026-04-15 |
Multiple System Atrophy (4) · Movement Disorders (2) · Neurodegenerative Diseases (2) · Primary Dysautonomias (2) · Shy-Drager Syndrome (2) · Synucleinopathies (2)
8-hydroxyquinazolin-4(3H)-one (3) · ATH434 (3)
France (2) · United States (2) · Australia (1) · Italy (1) · New Zealand (1) · United Kingdom (1)
2025 (1)